Home > Urology > EAU 2021 > Prostate Cancer > Radiographic PFS benefit of adding abiraterone to ADT and docetaxel in mCSPC

Radiographic PFS benefit of adding abiraterone to ADT and docetaxel in mCSPC

Presented By
Prof. Karim Fizazi, University of Paris-Saclay, Villejuif, France
Conference
EAU 2021
Trial
Phase 3, PEACE-1
Adding abiraterone to androgen deprivation therapy (ADT) and docetaxel significantly improved radiographic progression-free survival (rPFS) in men with de novo metastatic castration-sensitive prostate cancer (mCSPC). This benefit is seen both in high-volume and low-volume metastatic disease. There was no meaningful additional short-term toxicity. In the last decade, the standard of care (SOC) for men with mCSPC has changed dramatically. Initially, ADT alone was SOC for these patients. In 2015, docetaxel was shown to improve survival. Two years later, the LATITUDE and STAMPEDE trials showed a survival advantage of the addition of abiraterone. In 2019, two additional trials confirmed the advantage of adding 2 other anti-androgen pathway signalling inhibitors, apalutamide or enzalutamide. Radiotherapy to the prostate for oligometastatic (low-volume) disease has also been shown to improve overall survival. The accrual of the phase 3 PEACE-1 trial (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on